RAC media coverage, page-1392

The world knowing about RAC is general marketing and investor marketing. I would probably agree that there could have been more of this, but ultimately for what purpose- ST SP increases? It needs to be sustained with substance. The SP will truly move when big pharma is interested and this is who the under the radar strategy was about. Getting through the programs and trials is what should be the primary focus of the Board, which is where I think they are at. Unfortunately, I think it will be choppy SP wise at least until we have some of the more valuable news arrive.... but I don't plan on selling either just have to stomach the SP rollercoaster...